메뉴 건너뛰기
Leukemia Research
Volumn 36, Issue 8, 2012, Pages 1071-1073
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
Author keywords

5 Azacitidine; Chronic myelomonocytic leukemia; Hypomethylating agents; Myelodysplasia
Indexed keywords

AZACITIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; INTERFERON; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;
EID: 84862513949     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.024     Document Type: Article
Times cited : (49)
References (8)
  • 1
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    • July
    • Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(July (5)):937-951.
    • (2009) Blood , vol.114 , Issue.5 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3    Brunning, R.D.4    Borowitz, M.J.5    Porwit, A.6
  • 2
    • 2542537480 scopus 로고    scopus 로고
    • Risk assessment in chronic myelomonocytic leukemia (CMML)
    • July
    • Germing U., Kundgen A., Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004, 45(July (7)):1311-1318.
    • (2004) Leuk Lymphoma , vol.45 , Issue.7 , pp. 1311-1318
    • Germing, U.1    Kundgen, A.2    Gattermann, N.3
  • 3
    • 70350720044 scopus 로고    scopus 로고
    • MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    • October
    • Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114(October (16)):3448-3458.
    • (2009) Blood , vol.114 , Issue.16 , pp. 3448-3458
    • Figueroa, M.E.1    Skrabanek, L.2    Li, Y.3    Jiemjit, A.4    Fandy, T.E.5    Paietta, E.6
  • 4
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    • March
    • Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(March (3)):223-232.
    • (2009) Lancet Oncol , vol.10 , Issue.3 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3    Santini, V.4    Finelli, C.5    Giagounidis, A.6
  • 5
    • 79958794151 scopus 로고    scopus 로고
    • Activity of azacitidine in chronic myelomonocytic leukemia
    • June
    • Costa R., Abdulhaq H., Haq B., Shadduck R.K., Latsko J., Zenati M., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117(June (12)):2690-2696.
    • (2011) Cancer , vol.117 , Issue.12 , pp. 2690-2696
    • Costa, R.1    Abdulhaq, H.2    Haq, B.3    Shadduck, R.K.4    Latsko, J.5    Zenati, M.6
  • 6
    • 84856657348 scopus 로고    scopus 로고
    • TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia
    • Perez C., Martinez-Calle N., Martin-Subero J.I., Segura V., Delabesse E., Fernandez-Mercado M., et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 2012, 7(2):e31605.
    • (2012) PLoS One , vol.7 , Issue.2
    • Perez, C.1    Martinez-Calle, N.2    Martin-Subero, J.I.3    Segura, V.4    Delabesse, E.5    Fernandez-Mercado, M.6
  • 7
    • 39049137353 scopus 로고    scopus 로고
    • Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
    • April
    • Wijermans P.W., Ruter B., Baer M.R., Slack J.L., Saba H.I., Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008, 32(April (4)):587-591.
    • (2008) Leuk Res , vol.32 , Issue.4 , pp. 587-591
    • Wijermans, P.W.1    Ruter, B.2    Baer, M.R.3    Slack, J.L.4    Saba, H.I.5    Lubbert, M.6
  • 8
    • 33846011361 scopus 로고    scopus 로고
    • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    • January
    • Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109(January (1)):52-57.
    • (2007) Blood , vol.109 , Issue.1 , pp. 52-57
    • Kantarjian, H.1    Oki, Y.2    Garcia-Manero, G.3    Huang, X.4    O'Brien, S.5    Cortes, J.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.